Clostridium perfringens bacteriophage Clo-PEP-2 and use for inhibiting Clostridium perfringens proliferation of same
Inventors
Yoon, Seong Jun • JUN, Soo Youn • Paik, Hyoun Rok • Son, Jee Soo • SHIN, Hee Jeong • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11529406-B2
Publication Date
2022-12-20
Expiration Date
Abstract
The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
Core Innovation
The invention relates to Siphoviridae bacteriophage Clo-PEP-2, deposited under the accession number KCTC 13185BP, having a genome set forth in SEQ ID NO: 1. The Siphoviridae bacteriophage Clo-PEP-2 is isolated from nature and has an ability to kill Clostridium perfringens.
A method is provided for preventing or treating a disease caused by Clostridium perfringens by administering, to an animal other than a human, a composition comprising an effective amount of Siphoviridae bacteriophage Clo-PEP-2 with the genome set forth in SEQ ID NO: 1 and deposited under KCTC 13185BP. The disclosure frames Clo-PEP-2 as an active ingredient for preventing or treating diseases caused by Clostridium perfringens.
The disclosure includes characterization of Clo-PEP-2 as a Siphoviridae bacteriophage, including its genome and open reading frames, and reports that it kills Clostridium perfringens strains while not being selected other bacteria. Experimental support is described for inhibition of Clostridium perfringens growth and for prevention and treatment outcomes in livestock and poultry.
Claims Coverage
The independent claim provides coverage for a non-human-animal method for preventing or treating a disease caused by Clostridium perfringens using a composition specified by both a genome reference and a deposited accession number, and relying on the phage’s ability to kill Clostridium perfringens. It includes one inventive feature as stated in the claim.
Preventing or treating a Clostridium perfringens disease with Clo-PEP-2 in a non-human animal
Administering to an animal other than a human a composition comprising an effective amount of Siphoviridae bacteriophage Clo-PEP-2 having a genome set forth in SEQ ID NO: 1 and deposited under the accession number KCTC 13185BP, which has an ability to kill Clostridium perfringens.
The claim scope is directed to administering to non-human animals an effective amount of Siphoviridae bacteriophage Clo-PEP-2 defined by SEQ ID NO: 1 and KCTC 13185BP and having an ability to kill Clostridium perfringens, for preventing or treating a disease caused by Clostridium perfringens.
Stated Advantages
High specificity and reduced impact on commensal flora are described in the summary content.
Reduces fecal detection and diarrhea in weaning pigs, and reduces fecal C. perfringens counts in chicks.
Reduction of mortality in chicken farming using feed, drinking water, or disinfectant formulations containing the phage.
Documented Applications
Prevention of disease outcomes in weaning pigs, including fecal detection and diarrhea index changes, associated with administration of Clo-PEP-2 compositions.
Treatment-associated reduction of fecal C. perfringens counts in chicks associated with Clo-PEP-2 compositions.
Chicken-farming mortality reduction using feed, drinking water, or disinfectant formulations containing Clo-PEP-2.
Use of Clo-PEP-2 as an active ingredient in pharmaceutical formulations, disinfectant formulations, and drinking-water or feed additive formulations.
Interested in licensing this patent?